If besting the market was impossible, the market wouldn’t be flooded with investors trying every trick in the book to beat it. Active trading creates the market, but outperforming it with any consistency is extremely difficult. Former advisor-turned-“fin-fluencer” Humphrey Yang would agree with the above. But for Yang, taking on the stock market is a pointless battle for people who want to get rich. The popular social media magnate, who has 1.83 million YouTube subscribers and 3.4 million TikTok followers ...

Core Insights - The article compares the performance of an All-Weather Portfolio with the S&P 500, highlighting the significant year-to-date return of 73% for the All-Weather Portfolio in 2025 [1][3]. Group 1: Portfolio Performance - The All-Weather Portfolio has achieved a 73% year-to-date return in 2025, indicating strong performance compared to traditional market indices [3]. - The S&P 500 serves as a benchmark for evaluating the effectiveness of different investment strategies [1]. Group 2: Investment Strategies - The Financial Prophet promotes a Covered Call Dividend Plan, suggesting that investors can earn up to 50% on certain investments [3]. - The Daily Prophet Report is positioned as a valuable resource for investors, providing essential information before market openings [3].

Beating the market is hard, and lately, winning new money even harder. Yet two Wall Street bulls with social-media megaphones are doing both, just as many stock pickers are watching their clients walk away https://t.co/AfKm3KqmeI ...

Eli Lilly - Eli Lilly has been a top-performing pharmaceutical company over the past decade, driven by significant clinical breakthroughs, particularly with tirzepatide, a dual GLP-1/GIP agonist approved by the FDA [2][4] - The company is expected to continue strong top-line growth from tirzepatide, which has been on the market for about three years, and positive results from recent clinical trials for orforglipron have boosted stock performance [4][8] - Eli Lilly is developing retatrutide, a "triple G" drug that targets three gut hormones, and has 11 weight loss candidates in its pipeline, positioning it as a leader in the competitive weight loss market [5][6] - The company received FDA approval for Kisunla for Alzheimer's treatment, marking a significant achievement in a field with few recent approvals [6] - Despite challenges in 2025 due to tariff volatility and disappointing guidance, Eli Lilly is shifting manufacturing back to the U.S., which should mitigate risks from trade policies [7] - The stock's forward price-to-earnings ratio is around 33, which is double the healthcare industry average, but justified by the company's strong performance and growth prospects; dividends have increased by 200% over the past decade [8] DexCom - DexCom specializes in continuous glucose monitoring (CGM) systems, offering superior technology compared to traditional blood glucose meters, providing constant monitoring and frequent updates [9][10] - The adoption of CGM technology has been a significant growth driver, with increasing patient transitions to CGM and better reimbursement from third-party payers leading to rising revenues [10][12] - The CGM market remains underpenetrated in the U.S., with many diabetes patients still not using CGM despite insurance coverage, indicating substantial growth potential [12] - DexCom faces competition from Abbott Laboratories but continues to thrive, with only 1% of diabetic adults globally having access to CGM, suggesting room for multiple successful players [13] - The company has domestic manufacturing capabilities, which should minimize the impact of tariffs, and its forward P/E ratio of around 42, while high, is not unprecedented for a high-growth stock [14][16]